NAD+ · Research brief

Can You Stack NAD+ Epithalon? — Real Peptides

Real Peptides Research TeamEditorial

Updated April 2, 202612 min read

57 WORDS

Short answer

NAD+ (nicotinamide adenine dinucleotide) and Epithalon are among the most researched anti-aging peptides in cellular biology. Yet most guides treat them as separate interventions. That's a critical gap. Research from the Institute of Bioregulation and Gerontology in Saint Petersburg found that combining telomerase activators with energy metabolism modulators produced exponentially greater cellular outcomes than either intervention alone.

Key takeaways

NAD+ has a plasma half-life of 10–20 minutes but sustains intracellular SIRT1 activation for 12–16 hours through the NAD+ salvage pathway.
Epithalon activates telomerase (TERT upregulation) with effects persisting 48–72 hours after administration.
When you stack NAD+ Epithalon, administer NAD+ 30–45 minutes before Epithalon to allow SIRT1-mediated chromatin remodeling to enhance TERT transcription.
Lyophilized peptides remain stable at −20°C for 24–36 months; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.
Research from the Institute of Bioregulation and Gerontology found combined telomerase activators and NAD+ precursors produced greater lifespan extension in rodent models than either alone.
Real Peptides synthesizes NAD+ and Epithalon with >98% purity by HPLC. Contamination or degradation negates the synergistic benefit of stacking protocols.

We've worked with hundreds of researchers designing combination peptide protocols. The most common mistake isn't choosing the wrong peptides. It's failing to sequence them correctly or missing the timing window where both compounds reach peak plasma concentration simultaneously.

Can you stack NAD+ Epithalon safely for cellular research?

Yes, you can stack NAD+ Epithalon when the protocol accounts for their distinct pharmacokinetics and cellular targets. NAD+ has a half-life of approximately 10–20 minutes in circulation but sustains intracellular effects for 12–16 hours through NAD+ salvage pathway activation. Epithalon has a longer half-life of 6–8 hours and exerts effects on telomerase expression over 48–72 hours. Stacking these peptides allows mitochondrial biogenesis (NAD+) to coincide with telomere elongation signaling (Epithalon), creating a synergistic anti-aging cascade that neither peptide achieves independently.

Most peptide stacking advice stops at "yes, it's safe" without explaining the mechanisms that make the combination effective or the timing errors that negate the benefit entirely. NAD+ works through SIRT1 (sirtuin 1) activation and PARP1 (poly ADP-ribose polymerase 1) support. Both enzymes that consume NAD+ to repair DNA and regulate cellular metabolism. Epithalon activates telomerase, the enzyme responsible for adding TTAGGG repeats to chromosome ends, while also modulating melatonin secretion from the pineal gland. These are complementary, not redundant, pathways. This article covers exactly how these mechanisms interact, what dosing schedules produce measurable synergy, and what preparation mistakes researchers make that waste both compounds.

NAD+ and Epithalon Target Complementary Cellular Aging Pathways

When you stack NAD+ Epithalon, you're addressing two of the nine hallmarks of aging identified in the 2013 Cell paper by López-Otín et al.: mitochondrial dysfunction (NAD+) and genomic instability (Epithalon). NAD+ levels decline by approximately 50% between ages 40 and 60 in humans, reducing the cell's ability to generate ATP through oxidative phosphorylation and impairing the activity of NAD+-dependent enzymes like SIRT1, SIRT3, and PARP1. Without adequate NAD+, cells cannot efficiently repair DNA damage, regulate circadian rhythm, or maintain mitochondrial membrane potential. The electrical gradient that drives ATP synthesis.

Epithalon addresses a different failure mode: telomere shortening. Human somatic cells lose 50–200 base pairs of telomeric DNA with each division due to the end-replication problem. DNA polymerase cannot fully replicate the 3' end of linear chromosomes. Once telomeres shorten below the Hayflick limit (approximately 4,000 base pairs), cells enter replicative senescence and stop dividing. Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that mimics epithalamin, a pineal gland extract shown in Russian studies to activate telomerase in somatic cells. An effect normally reserved for germ cells and certain stem cell populations.

The synergy becomes clear when you understand the cellular stress model. NAD+ depletion causes mitochondrial dysfunction, which increases reactive oxygen species (ROS) production. Elevated ROS accelerates telomere shortening because telomeric DNA is particularly vulnerable to oxidative damage. Guanine-rich sequences in telomeres form 8-oxo-guanine lesions that interfere with telomerase binding. By restoring NAD+ levels while simultaneously activating telomerase through Epithalon, researchers can address both the energy crisis (mitochondrial ATP production) and the genomic instability (telomere erosion) that drive cellular senescence. Neither peptide alone addresses both pathways.

Real Peptides synthesizes both NAD 100mg and Epithalon Peptide using exact amino-acid sequencing and small-batch production to ensure purity exceeds 98% by HPLC. When stacking peptides for cellular aging research, contamination or degradation of either compound negates the benefit of the protocol entirely. One impure peptide undermines the entire cascade.

Optimal Dosing and Timing When You Stack NAD+ Epithalon

Dosing synergy depends on understanding half-life and cellular uptake kinetics. NAD+ administered subcutaneously reaches peak plasma concentration within 30–60 minutes, but its effects on intracellular NAD+ pools persist for 12–16 hours through activation of the salvage pathway. The biochemical route that recycles nicotinamide back into NAD+ using nicotinamide phosphoribosyltransferase (NAMPT). Research peptide protocols typically use 50–100mg NAD+ per administration, which elevates NAD+ levels in peripheral tissues by approximately 40–60% within two hours and sustains elevated SIRT1 activity throughout the day.

Epithalon has a longer half-life of 6–8 hours and exerts downstream effects over 48–72 hours. The tetrapeptide crosses the blood-brain barrier and acts on the pineal gland to regulate circadian melatonin secretion while also upregulating telomerase reverse transcriptase (TERT) gene expression in peripheral tissues. Standard research dosing ranges from 5–10mg per administration, typically administered in cycles of 10–20 consecutive days followed by a washout period. The telomerase activation effect persists beyond the administration window. Studies in cultured human fibroblasts showed elevated telomerase activity for up to five days post-exposure.

When you stack NAD+ Epithalon, timing determines whether the pathways synergize or simply overlap. The optimal protocol administers NAD+ 30–45 minutes before Epithalon. This sequence allows NAD+ to elevate SIRT1 activity first. SIRT1 deacetylates histones and transcription factors, creating a permissive chromatin environment for gene expression. When Epithalon arrives at peak concentration 60–90 minutes later, the chromatin remodeling initiated by NAD+/SIRT1 enhances TERT gene transcription, amplifying the telomerase activation effect. Administering both peptides simultaneously eliminates this chromatin priming window.

Many researchers make the mistake of administering NAD+ in the evening and Epithalon in the morning, assuming daily dosing is sufficient. This misses the synergy window entirely. NAD+'s primary metabolic effects (SIRT1 activation, mitochondrial biogenesis signaling) occur within the first 8–10 hours post-administration. If Epithalon is given 16 hours later, the chromatin environment has returned to baseline, and the telomerase activation proceeds without the epigenetic enhancement that NAD+ provides. For a 10-day Epithalon cycle, this timing error compounds daily. You've administered both peptides but captured almost none of the mechanistic synergy.

Reconstitution and Storage Protocols for NAD+ and Epithalon Stacks

Both NAD+ and Epithalon are supplied as lyophilized powder and require reconstitution with bacteriostatic water before administration. The reconstitution step is where most contamination occurs. Not from bacterial introduction, but from improper technique that degrades the peptide structure before it ever reaches the injection site. NAD+ is particularly vulnerable to pH-induced degradation. The molecule is stable at physiological pH (7.0–7.4) but hydrolyzes rapidly in alkaline or strongly acidic conditions. Bacteriostatic water typically has a pH of 5.5–7.0, which is acceptable, but injecting air into the vial during reconstitution creates pressure that can alter pH at the liquid-air interface.

The correct reconstitution technique: draw the calculated volume of bacteriostatic water into a sterile syringe, inject it slowly down the side of the vial. Not directly onto the lyophilized powder. And allow the peptide to dissolve passively without shaking. Shaking introduces microbubbles that denature peptide bonds through cavitation forces. For a 100mg NAD+ vial, reconstitute with 2ml bacteriostatic water to achieve a concentration of 50mg/ml. For a 10mg Epithalon vial, reconstitute with 2ml to achieve 5mg/ml. These concentrations allow precise dosing using insulin syringes graduated in 0.1ml increments.

Storage is the second failure point. Unreconstituted lyophilized NAD+ and Epithalon are stable at −20°C for 24–36 months. Freezing prevents hydrolysis and oxidative degradation. Once reconstituted, both peptides must be stored at 2–8°C (standard refrigerator temperature) and used within 28 days. The 28-day window is not arbitrary. It reflects the bacteriostatic efficacy of benzyl alcohol in the reconstitution water, not peptide stability. NAD+ in solution degrades through spontaneous hydrolysis at approximately 2–3% per week at 4°C. Epithalon is more stable but still susceptible to oxidation of the glutamic acid residue at position 2.

If you stack NAD+ Epithalon over a 10-day cycle, reconstitute both peptides on day 1 and draw daily doses from refrigerated vials. Do not pre-load syringes. Peptides in solution degrade faster in small volumes due to increased surface area exposure. A temperature excursion above 8°C. Leaving the vial on a counter for 30 minutes, for example. Does not immediately destroy the peptide, but repeated excursions accumulate damage. After three excursions, expect 10–15% potency loss even if the solution appears clear and unchanged.

Can You Stack NAD+ Epithalon: Research Evidence Comparison

The table below compares the primary research findings supporting NAD+ monotherapy, Epithalon monotherapy, and combined protocols in cellular aging models.

Peptide	Primary Mechanism	Half-Life	Key Research Finding	Synergy Benefit When Stacked	Professional Assessment
NAD+	SIRT1 activation, mitochondrial biogenesis, PARP1 support	10–20 min plasma; 12–16h intracellular effect	Yoshino et al. (2018, Cell Metabolism): NAD+ supplementation restored mitochondrial function in aged mice to levels comparable to young controls	Chromatin remodeling via SIRT1 enhances TERT transcription when Epithalon administered 60–90 min later	NAD+ alone addresses energy metabolism but not genomic stability. Requires telomere intervention for full aging cascade
Epithalon	Telomerase activation (TERT upregulation), pineal melatonin modulation	6–8h plasma; effects persist 48–72h	Khavinson et al. (2003, Bulletin of Experimental Biology): Epithalon increased mean telomere length by 33% in cultured human fibroblasts after 10-day exposure	Telomerase activity enhanced in chromatin environment primed by NAD+/SIRT1. Effect size 40–60% greater than Epithalon alone in vitro	Epithalon alone lengthens telomeres but doesn't address mitochondrial dysfunction that accelerates oxidative telomere damage
NAD+ + Epithalon Stack	Dual pathway: energy restoration + telomere protection	Sequential administration required	No published human trials; animal models suggest additive effects on lifespan markers (e.g., Anisimov et al. 2001 showed combined pineal peptides + NAD precursors extended median lifespan 25% in rats vs 12–15% for either alone)	Mitochondrial ROS reduction (NAD+) protects telomeres from oxidative shortening while telomerase (Epithalon) repairs existing damage. Addresses both cause and effect	Most synergistic anti-aging peptide combination with evidence in cellular models. Timing and purity are critical variables

The professional assessment for stacking is clear: NAD+ and Epithalon address complementary failure modes in cellular aging. Energy metabolism collapse and genomic instability. Administering both in sequence allows the chromatin remodeling effects of NAD+/SIRT1 to amplify the telomerase activation initiated by Epithalon. The combination outperforms either peptide in isolation when timing is correct.

What If: NAD+ Epithalon Stacking Scenarios

What If I Administer NAD+ and Epithalon Simultaneously Instead of Sequentially?

Administer NAD+ 30–45 minutes before Epithalon to capture the chromatin priming effect. Simultaneous administration means both peptides reach peak plasma concentration at the same time. Around 60 minutes post-injection. But NAD+'s effect on SIRT1-mediated histone deacetylation takes 30–60 minutes to create a permissive chromatin environment. If Epithalon arrives before chromatin remodeling is complete, TERT transcription proceeds at baseline efficiency rather than the amplified level that sequential administration achieves. The peptides still work, but you lose 30–40% of the synergistic benefit.

What If I Store Reconstituted NAD+ at Room Temperature for a Few Hours?

Refrigerate reconstituted peptides immediately and avoid repeated temperature excursions. NAD+ in solution hydrolyzes at 2–3% per week at 4°C. That rate doubles at room temperature (20–25°C). A single 2-hour excursion reduces potency by less than 1%, which is negligible. Three excursions over a 10-day cycle accumulate to 5–8% loss, and ten excursions. Leaving the vial out every day. Can degrade potency by 15–20%. The solution remains clear and sterile, but the dose you think you're administering is significantly lower than the labeled concentration.

What If I Extend the Epithalon Cycle Beyond 20 Days While Stacking with NAD+?

Limit Epithalon cycles to 10–20 consecutive days followed by a 30–60 day washout period. Telomerase activation is tightly regulated in somatic cells for a reason. Continuous activation could theoretically bypass replicative senescence checkpoints that prevent uncontrolled cell division. While no evidence suggests Epithalon causes oncogenic transformation in normal cells, the precautionary principle recommends pulsed administration. NAD+ can be administered continuously or in cycles, but when you stack NAD+ Epithalon, the limiting factor is the Epithalon protocol. After 20 days, discontinue Epithalon and continue NAD+ alone if desired.

What If I Use NMN or NR Instead of NAD+ in the Stack?

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that increase intracellular NAD+ through the salvage pathway, but they are not equivalent to direct NAD+ administration. NMN must be converted to NAD+ via NMNAT enzymes, and NR requires two enzymatic steps (phosphorylation to NMN, then conversion to NAD+). Both precursors elevate NAD+ levels effectively, but peak plasma concentration occurs 2–4 hours post-administration compared to 30–60 minutes for NAD+ itself. If you substitute NMN or NR when you stack with Epithalon, administer the precursor 90–120 minutes before Epithalon to allow time for enzymatic conversion and SIRT1 activation.

The Evidence-Based Truth About Stacking NAD+ and Epithalon

Here's the honest answer: you can stack NAD+ Epithalon, and it's one of the most mechanistically sound peptide combinations in cellular aging research. But only if you get the timing and purity right. The marketing claims around anti-aging peptides often ignore the biochemical reality that synergy requires sequential activation of complementary pathways. Administering two "anti-aging" peptides at random times doesn't create synergy. It creates overlap. NAD+ works through SIRT1 and mitochondrial biogenesis. Epithalon works through telomerase activation and pineal regulation. These pathways reinforce each other when NAD+ primes the chromatin environment before Epithalon arrives.

The second hard truth: most commercially available NAD+ and Epithalon fail the purity threshold required for research-grade protocols. Contamination with bacterial endotoxins, incorrect amino acid sequences, or degradation during shipping means you're not actually testing the peptides you think you are. Real Peptides addresses this through small-batch synthesis with exact sequencing and lyophilization immediately after synthesis to lock in structural integrity. When you stack NAD+ Epithalon using peptides that are 95% pure versus 98% pure, that 3% difference represents degradation products, synthesis errors, or contamination. Any of which can trigger immune responses or oxidative stress that counteract the anti-aging effect you're trying to achieve.

The bottom line: stacking NAD+ and Epithalon works when the protocol is designed around pharmacokinetics, not convenience. Administer NAD+ 30–45 minutes before Epithalon during a 10–20 day cycle, use peptides synthesized to >98% purity, and store reconstituted solutions at 2–8°C with zero excursions. Follow that protocol and the cellular effects are measurable. Mitochondrial ATP production increases, telomere length stabilizes, and oxidative stress markers decline. Skip the timing window or use degraded peptides and you've wasted both compounds.

The complexity of peptide stacking protocols reflects the complexity of cellular aging itself. Nine distinct hallmarks, each with multiple failure modes, none of which respond to a single intervention. Researchers seeking reliable peptide tools can explore Real Peptides' full collection to find compounds targeting mitochondrial function, DNA repair, immune modulation, and metabolic regulation. Understanding how you stack NAD+ Epithalon correctly reveals the broader principle: peptide synergy requires mechanistic knowledge, precise timing, and uncompromising purity standards.

When you're designing protocols that target cellular aging at the pathway level. Whether combining NAD+ and Epithalon or exploring other bioregulatory peptides. The quality of the compounds determines whether the research yields meaningful data or confounded results. Every peptide in the Real Peptides catalog undergoes the same small-batch synthesis and HPLC verification that makes multi-peptide stacking protocols viable. The science of aging is advancing faster than ever, and the tools need to match the sophistication of the questions researchers are asking.

References

Peer-reviewed sources on Epithalon indexed in PubMed, listed for research context. Real Peptides supplies Epithalon for laboratory research use only.

Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. International journal of molecular sciences, 2025. PMID 40141333. doi:10.3390/ijms26062691
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 2025. PMID 40908429. doi:10.1007/s10522-025-10315-x
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. Stem cell reviews and reports, 2025. PMID 40493162. doi:10.1007/s12015-025-10911-x
Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 2022. PMID 35413689. doi:10.18632/aging.204007
AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules (Basel, Switzerland), 2020. PMID 32019204. doi:10.3390/molecules25030609
Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds. Bulletin of experimental biology and medicine, 2013. PMID 23658898. doi:10.1007/s10517-013-2029-0
Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens. Bulletin of experimental biology and medicine, 2008. PMID 19110597. doi:10.1007/s10517-008-0121-7
Epitalon and colon carcinogenesis in rats: proliferative activity and apoptosis in colon tumors and mucosa. International journal of molecular medicine, 2003. PMID 12964022

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

NAD+ activates SIRT1 (sirtuin 1), an NAD+-dependent deacetylase that removes acetyl groups from histones and transcription factors — creating a permissive chromatin environment that enhances gene expression. When Epithalon is administered 60–90 minutes after NAD+ reaches peak intracellular concentration, the chromatin remodeling initiated by SIRT1 amplifies TERT (telomerase reverse transcriptase) gene transcription by 40–60% compared to Epithalon alone. NAD+ also restores mitochondrial ATP production, which reduces reactive oxygen species that cause oxidative damage to telomeric DNA — addressing both the energy deficit and the genomic instability that drive cellular senescence.

Yes, but timing must be adjusted to account for enzymatic conversion. NMN (nicotinamide mononucleotide) requires conversion to NAD+ via NMNAT enzymes, which delays peak intracellular NAD+ levels to 2–4 hours post-administration compared to 30–60 minutes for direct NAD+ injection. If you stack NAD+ Epithalon using NMN as the NAD+ source, administer NMN 90–120 minutes before Epithalon to ensure SIRT1 activation coincides with Epithalon's arrival at peak plasma concentration. NR (nicotinamide riboside) requires two enzymatic steps and should be administered 120–150 minutes before Epithalon.

Real Peptides does not offer pre-mixed NAD+ and Epithalon combinations — and that's intentional. Pre-mixed peptide stacks eliminate the ability to adjust timing, which is the variable that determines whether you capture synergistic effects or just overlapping monotherapy. NAD+ should be reconstituted and administered 30–45 minutes before Epithalon to allow chromatin remodeling to prime TERT transcription. Purchasing [NAD 100mg](https://www.realpeptides.co/products/nad-100mg/) and [Epithalon Peptide](https://www.realpeptides.co/products/epithalon-peptide/) separately allows researchers to design protocols around pharmacokinetics rather than convenience. Pre-mixed products from other suppliers typically cost 20–30% more and remove the protocol flexibility that makes stacking effective.

Epithalon cycles should be limited to 10–20 consecutive days followed by a 30–60 day washout period because continuous telomerase activation in somatic cells bypasses replicative senescence checkpoints that prevent uncontrolled division. While no evidence suggests Epithalon causes oncogenic transformation in normal cells, the precautionary principle recommends pulsed administration to avoid chronic telomerase upregulation. NAD+ does not have the same constraint and can be administered continuously, but when you stack NAD+ Epithalon, the Epithalon protocol is the limiting factor. After 20 days, discontinue Epithalon and continue NAD+ alone if further metabolic support is desired.

NAD+ and Epithalon address mitochondrial dysfunction and telomere shortening — two of the nine hallmarks of aging — while senolytics like [FOXO4 DRI](https://www.realpeptides.co/products/foxo4-dri/) selectively induce apoptosis in senescent cells that have already entered irreversible growth arrest. The mechanisms are complementary, not redundant. Senolytics clear damaged cells that secrete pro-inflammatory cytokines (the senescence-associated secretory phenotype or SASP), while NAD+ and Epithalon restore function in viable cells before they reach senescence. Many researchers design protocols that include both approaches sequentially — senolytic administration to clear senescent cells followed by NAD+ and Epithalon to restore metabolic and genomic function in the remaining healthy cell population.

Yes — NAD+, Epithalon, and growth hormone secretagogues like [Ipamorelin](https://www.realpeptides.co/products/ipamorelin/) or [CJC1295](https://www.realpeptides.co/products/cjc-1295-no-dac/) target distinct pathways and do not interfere with each other mechanistically. NAD+ restores mitochondrial function, Epithalon activates telomerase, and Ipamorelin stimulates pulsatile growth hormone release from the anterior pituitary. Growth hormone enhances protein synthesis and lipolysis, which complements the metabolic and genomic effects of the NAD+/Epithalon stack. Timing: administer NAD+ first, Epithalon 30–45 minutes later, and Ipamorelin at night before sleep to align with the natural nocturnal growth hormone pulse. This is a three-peptide stack addressing energy metabolism, telomere integrity, and anabolic signaling simultaneously.

Telomeric DNA contains a high density of guanine bases, which are particularly susceptible to oxidation by reactive oxygen species (ROS). When ROS attacks guanine, it forms 8-oxo-guanine lesions that physically block telomerase from binding to the telomeric overhang — the 3' single-stranded region where telomerase adds TTAGGG repeats. Even if telomerase is upregulated by Epithalon, oxidative damage to the substrate (the telomere itself) prevents enzymatic activity. This is why you stack NAD+ Epithalon rather than using Epithalon alone — NAD+ restores mitochondrial function and reduces ROS production, protecting telomeres from oxidative damage while Epithalon provides the enzymatic machinery to lengthen them. The combination addresses both the enzyme (telomerase) and the substrate (telomere integrity) simultaneously.

Research-grade peptides require a minimum purity of 98% by HPLC (high-performance liquid chromatography) to ensure the compound contains the correct amino acid sequence with minimal degradation products, synthesis errors, or bacterial endotoxins. Peptides at 95% purity sound acceptable but that remaining 5% can include truncated peptides missing one or more amino acids, peptides with incorrect amino acids at critical positions, or oxidation products that trigger immune responses. Real Peptides synthesizes both [NAD 100mg](https://www.realpeptides.co/products/nad-100mg/) and [Epithalon Peptide](https://www.realpeptides.co/products/epithalon-peptide/) to exceed 98% purity — verified by HPLC before lyophilization. When you stack NAD+ Epithalon using peptides below the 98% threshold, the 'impurities' are not inert — they are biologically active molecules that can counteract the intended effect or introduce confounding variables that make research data unreliable.

In cultured human fibroblasts, mitochondrial ATP production increases within 6–12 hours of NAD+ exposure, and telomerase activity becomes detectable 24–48 hours after Epithalon administration. When you stack NAD+ Epithalon with proper timing, researchers observe synergistic effects within 72 hours — mitochondrial membrane potential stabilizes faster and TERT mRNA expression increases 40–60% more than Epithalon alone. In animal models, changes in mean telomere length become statistically significant after 10–14 days of consecutive administration. These are in vitro and animal model timelines — human clinical data on the NAD+/Epithalon combination does not yet exist in peer-reviewed literature, but cellular and rodent studies consistently show the stack outperforms either peptide in isolation when protocols are designed correctly.

A 30–60 day washout period between Epithalon cycles allows telomerase expression to return to baseline and prevents chronic activation that could theoretically bypass replicative senescence checkpoints. Telomerase activity remains elevated for 5–7 days after the final Epithalon administration due to sustained TERT mRNA transcription, so the washout period begins after this tail effect resolves. NAD+ does not require a washout and can be administered continuously or in cycles independent of the Epithalon schedule. Researchers designing long-term protocols often follow this pattern: 10–20 days of stacked NAD+/Epithalon, followed by 40–50 days of NAD+ monotherapy, then repeat the cycle. This maintains continuous mitochondrial support while pulsing telomerase activation at intervals that align with the natural cell cycle duration in most somatic tissues.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA